NeoPharm CO. LTD (092730) — Cash Flow Quality Index
NeoPharm CO. LTD (092730) has a Cash Flow Quality Index of 0.86x as of September 2025. Operating cash flow of ₩5.88 Billion is below net income of ₩6.86 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore NeoPharm CO. LTD debt service capacity to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
NeoPharm CO. LTD Cash Flow Quality Index (2012–2024)
Historical Cash Flow Quality Index for NeoPharm CO. LTD across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see NeoPharm CO. LTD (092730) cash flow conversion.
Annual Cash Flow Quality Index for NeoPharm CO. LTD (2012–2024)
Year-by-year earnings quality comparison for NeoPharm CO. LTD.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.81x | ₩18.63 Billion | ₩23.06 Billion | ▼ -19.4% |
| 2023 | 1.00x | ₩23.26 Billion | ₩23.21 Billion | ▼ -6.0% |
| 2022 | 1.07x | ₩18.16 Billion | ₩17.03 Billion | ▼ -12.9% |
| 2021 | 1.22x | ₩21.68 Billion | ₩17.71 Billion | ▲ +30.0% |
| 2020 | 0.94x | ₩17.07 Billion | ₩18.13 Billion | ▼ -5.7% |
| 2019 | 1.00x | ₩19.22 Billion | ₩19.25 Billion | ▼ -5.1% |
| 2018 | 1.05x | ₩16.18 Billion | ₩15.37 Billion | ▲ +14.3% |
| 2017 | 0.92x | ₩10.65 Billion | ₩11.56 Billion | ▼ -22.1% |
| 2016 | 1.18x | ₩9.16 Billion | ₩7.74 Billion | ▼ -33.9% |
| 2015 | 1.79x | ₩6.09 Billion | ₩3.41 Billion | ▲ +105.3% |
| 2012 | 0.87x | ₩564.34 Million | ₩647.76 Million | — |